<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04503902</url>
  </required_header>
  <id_info>
    <org_study_id>JS001D-C-102</org_study_id>
    <nct_id>NCT04503902</nct_id>
  </id_info>
  <brief_title>Toripalimab Combined With Donafenib in the Treatment of Advanced Hepatocellular Carcinoma</brief_title>
  <acronym>HCC</acronym>
  <official_title>A Multi-center, Open, Dose Exploration and Dose Expansion Phase I/II Clinical Study of Toripalimab（JS001） Combined With Donafenib in Patients With Advanced Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzhou Zelgen Biopharmaceuticals Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suzhou Zelgen Biopharmaceuticals Co.,Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open, multi-center phase I/II clinical study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It will explore the tolerability (phase I) and effectiveness (phase II) of the Donafenib&#xD;
      tosilate tablets combined with Toripalimab injection in patients with advanced HCC. The study&#xD;
      is conducted in two phases, the first phase is the dose exploration phase (phase I), and the&#xD;
      second phase is the dose expansion phase (phase II).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicity (DLT)</measure>
    <time_frame>28 days after the first dose of JS001 and Donafenib</time_frame>
    <description>Severe toxicity that may be related to JS001 or donafenib during dose escalation of phase I clinical trial</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate（ORR） as determined by the Invertigator using RECIST V1.1</measure>
    <time_frame>From the time of initial administration until intolerant toxicity, disease progression, withdrawal of ICF, loss of follow-up, death or early study termination occurs (whichever occurs first),assessed up to 18 months</time_frame>
    <description>The ratio of patients who are evaluated as CR or PR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-JS001 antibody</measure>
    <time_frame>From the time of initial administration until intolerant toxicity, disease progression, withdrawal of ICF, loss of follow-up, death or early study termination occurs (whichever occurs first),assessed up to 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From the time of initial administration until intolerant toxicity, disease progression, withdrawal of ICF, loss of follow-up, death or early study termination occurs (whichever occurs first),assessed up to 18 months</time_frame>
    <description>The Kaplan-Meier survival from the initiation date of first cycle until death from any cause or the last follow-up date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>From the time of initial administration until intolerant toxicity, disease progression, withdrawal of ICF, loss of follow-up, death or early study termination occurs (whichever occurs first),assessed up to 18 months</time_frame>
    <description>The Kaplan-Meier survival from the initiation date of first cycle until the date of first documented progression or date of death</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Advanced Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>JS001+Donafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Donafenib 100mg QD/100 mg BID/200 mg BID orally + JS001 240mg Q3W iv</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donafenib Tosilate Tablets</intervention_name>
    <description>In the dose exploration phase (phase I)，three doses of Donafenib tosylate tablets [100 mg once a day (QD); 100 mg twice a day (BID); 200 mg, BID] will be explored. In the dose expansion phase (phase II), patients will be treated at the recommended dose for phase 2(RP2D).The RP2D will be determined by the dose escalation study.</description>
    <arm_group_label>JS001+Donafenib</arm_group_label>
    <other_name>Donafenib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Toripalimab Injection</intervention_name>
    <description>JS001 will be administrated by intravenous (i.v.) infusion once every 21 days</description>
    <arm_group_label>JS001+Donafenib</arm_group_label>
    <other_name>JS001</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with locally advanced or metastatic HCC who are not suitable for surgical&#xD;
             resection, who are clinically diagnosed or confirmed by histopathology and/or cytology&#xD;
             according to the &quot;Standards for the Diagnosis and Treatment of Primary Liver Cancer&quot;&#xD;
             (2017);&#xD;
&#xD;
          -  At least one measurable lesion (according to RECIST v1.1);&#xD;
&#xD;
          -  ECOG performance status score of 0 or 1;&#xD;
&#xD;
          -  Life expectancy ≥ 12 weeks；&#xD;
&#xD;
          -  Have not received systemic therapy (systemic chemotherapy and/or molecular targeted&#xD;
             therapy).If the patient has received adjuvant chemotherapy after local treatment, the&#xD;
             chemotherapy needs to be over for more than 12 months, and disease progression or&#xD;
             metastasis occurs；&#xD;
&#xD;
          -  Fully understand this research and voluntarily sign the ICF。&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with diffuse liver cancer, hepatic encephalopathy that is difficult to&#xD;
             control, and liver cancer patients whose lesion size accounts for 70% or more of the&#xD;
             entire liver.&#xD;
&#xD;
          -  Patients with intrahepatic cholangiocarcinoma (ICC) or HCC-ICC mixed type；&#xD;
&#xD;
          -  Tumor invades inferior vena cava VP4.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shukui Qin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>No.81 Hospital of PLA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shukui Qin, PhD</last_name>
    <phone>+86-025-80864541</phone>
    <email>qinsk@csco.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>No.81 Hospital of PLA</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shukui Qin</last_name>
      <phone>+86-025-80864541</phone>
      <email>qinsk@csco.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>August 3, 2020</study_first_submitted>
  <study_first_submitted_qc>August 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2020</study_first_posted>
  <last_update_submitted>April 30, 2021</last_update_submitted>
  <last_update_submitted_qc>April 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

